Research programme: eye disorder therapies - Handok Pharmaceuticals

Drug Profile

Research programme: eye disorder therapies - Handok Pharmaceuticals

Alternative Names: HL 3501; HL 5501; HL 5511; HL5521

Latest Information Update: 21 Aug 2014

Price : $50

At a glance

  • Originator Handok Inc
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Age-related macular degeneration; Diabetic macular oedema; Glaucoma

Most Recent Events

  • 21 Aug 2014 Early research is ongoing in South Korea
  • 01 Oct 2013 Early research in Age-related macular degeneration, Diabetic macular oedema and Glaucoma in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top